The Comeback Cat With More Than Nine Lives

The market has the memory of a goldfish and the gratitude of a cat. Pfizer (PFE) saved the world, then watched its stock get tossed out like last week’s leftovers. But the story isn’t over.

Not when the company is quietly stitching together a pipeline, beating estimates the analysts didn’t think it could beat, and positioning itself to ride the next multi-hundred‑billion‑dollar therapeutic wave.

If you think Pfizer’s best days are behind it, you haven’t been paying attention.

Start with Metsera – Pfizer’s quickest, cleanest acquisition in years. The moment Novo Nordisk (NVO) refused to sweeten its offer beyond $10 billion, Pfizer swooped in and closed the deal within five days.

Big Pharma rarely moves that fast unless it sees something worth moving for. And there was.

The MET-097i data released on September 29 showed a 14.1% placebo‑subtracted weight loss at 28 weeks with only a 2.9% discontinuation rate across dose groups. Very few GLP‑1 or amylin candidates show tolerability numbers that clean.

Only 2 of the 239 participants discontinued due to adverse events, marking a subtle but meaningful early sign of differentiation in a highly competitive field.

Meanwhile, Novo’s CagriSema posted an 8.4% discontinuation rate in REDEFINE 2, or nearly triple the rate seen with MET-097i. That discrepancy matters more than most retail investors realize.

In obesity medicine, tolerability is half the game. Doctors don’t like switching medications, and insurers don’t like paying for side-effect management.

Pfizer may have stumbled with danuglipron’s liver signals, but Metsera gives them another attempt with better fundamentals.

While the pipeline rebuild takes shape, the existing franchises continue to do far more heavy lifting than the market narrative acknowledges.

Eliquis brought in roughly $2.02 billion, up 24.6% year-over-year, despite a Canadian generic from Sandoz entering in 2022.

And with Bristol Myers Squibb (BMY) and Johnson & Johnson’s (JNJ) milvexian failing its pivotal Librexia ACS Phase 3 trial, one of the only serious competitive threats evaporated overnight. That buys Pfizer valuable time on a drug that’s still a revenue powerhouse.

Then there’s the quieter performers.

Lorbrena, Pfizer’s ALK inhibitor for non‑small cell lung cancer, delivered $268 million in Q3, up 30% year on year.

Vyndaqel, its transthyretin amyloidosis franchise, pulled in $1.6 billion, well above internal estimates.

The biosimilars business, often overlooked, continues to expand through Inflectra, Abrilada, and Retacrit, each carving share in a market projected to hit $72 billion by 2035.

Biosimilars may not be glamorous, but they produce recurring revenue with enviable margins once established.

Even Comirnaty and Paxlovid, written off by most investors as yesterday’s news, showed more resilience than expected, contributing a combined $2.38 billion last quarter. For a pair of products in what is supposed to be a “post‑COVID trough,” that’s hardly trivial.

And all of that flowed into a quarter that surprised on nearly every metric.

Revenue jumped from $14.7 billion in Q2 to $16.65 billion in Q3, a 13.7% sequential increase.

Non‑GAAP EPS came in at $0.87, beating consensus by $0.23 and even surpassing the most optimistic internal scenarios.

When you’re paying out roughly $2.4 billion per quarter in dividends, beating earnings by that margin is the difference between a stable payout and shareholder heartburn.

Of course, it isn’t all sunshine.

Padcev slipped 14.4% quarter-to-quarter to $464 million. Tukysa fell to $110 million, down 11.1% from the prior quarter. The $5 billion in newly issued debt raised questions about how many more acquisitions Pfizer can absorb.

And the patent cliffs ahead, particularly for Eliquis and Ibrance, aren’t rumors; they’re scheduled events.

But those risks aren’t the result of mismanagement; they’re the structural realities of running one of the world’s largest pharmaceutical portfolios.

What matters is how a company prepares for them. Pfizer is preparing with a broader metabolic pipeline, deeper oncology bets, strengthened biosimilar positioning, and ongoing cost discipline.

It’s not glamorous, but it’s deliberate.

And then there’s valuation. Trading near 7.8x earnings, roughly a 56% discount to the healthcare sector median, Pfizer doesn’t need breakout growth to rerate meaningfully. It simply needs consistency. The bar is not high.

People often forget that Big Pharma turnarounds rarely announce themselves with fireworks. They begin in the footnotes of trial data, the quiet quarters of incremental revenue beats, the steady plugging of pipeline gaps.

Pfizer is in that stage now: unfashionable to the crowd, but increasingly compelling to anyone looking past the headlines.

So while everyone else chases the new and the noisy, Pfizer is rebuilding in plain sight and setting the stage for a much stronger 2026 and beyond.

And if the market ever decides to remember what Pfizer brings to the table, well, maybe even cats will say thank you.